We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGL Angle Plc

-0.25 (-1.67%)
Last Updated: 14:01:00
Delayed by 15 minutes
Angle Investors - AGL

Angle Investors - AGL

Share Name Share Symbol Market Stock Type
Angle Plc AGL London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.25 -1.67% 14.75 14:01:00
Open Price Low Price High Price Close Price Previous Close
15.00 14.75 15.00 15.00
more quote information »
Industry Sector

Top Investor Posts

Top Posts
Posted at 23/7/2024 08:33 by ohwhatfun
Just read the AGM notes Timbo thanks, and replies.

Fund raise.

No some were not saying trouble fund raising, they said trouble raising the typical required amount £20m. Previous raises have been £20m with more cash in the bank at the time of the raise.

Had they raised £20m, as per posts, various new private investors would have bought, others would add. Instead you have a number of investors doubtful of revenue claims, knowing that event triggers negative news, and the miss shortens the time to the next raise.

Why it’s difficult to raise currently at prices and amounts is in the notes.
Some mention Avacta 50p raise 75p now, it was over £1 shortly before the raise, with posters trashing others who suggested a big discounted raise was coming.

Revenue this year

HOPE to get 2 more customers this year, what over £2m each against examples of £150k. Not confident or very confident, HOPE.

Oversubscribed raise, show me news of raises where they are not oversubscribed over the years. It’s been explained a number of times, fund raises are supposed to be closed circles but are far from it. In the subscribed list for AGL would have been demand to close short positions opened in knowledge of the raise.

Just about every raise sees the share price fall below the raise price, yet AGL seem oblivious to this, suggesting incompetence.

The loss of bread and butter small company revenue in this sector is evident in other companies, 75%+ revenue drops in some cases, explained as funding drying up. That’s not AGL that’s the sector.

AGLs fix was to proactively start chasing big Pharma.

All the confidence and loud claims now seems to be based on 2 with HOPE.

Hope based on hard-nosed sale tactics. Yeah the deal is you pay for everything, we keep the IP you create and paid for.
I fail to see the buyer carrot on a stick there, minnows trying to bully majors.

The hope of 2 more customers, needs to be done swiftly to count for revenue this year. It sounds like revenue is going to be missed by some way.

That’s not a good advert for new investors to buy now. Some don’t like coin flip investment timing
Posted at 19/7/2024 06:59 by bones698
Adw I'm interested to see how they play it this time. The last profit warning was a miss of 200k and had plenty of positives in the rns but all that was ignored and the share price got mulleted.

Will they release good news before it and boost the share price only to then see it get savaged on a profit warning soon after, or get the bad news out the way then have a couple of decent news releases?
Obviously there are not options but doesn't seem much point announcing good news if a profits warning comes soon after.

Either way I'll remain on the sidelines for now, it could be a mistake for sure there's always that chance but alps it could be a great oppurtunity too. The aim gamble is always fun. What's becoming clear is that holding shares for years isn't the best way to make money on aim anymore, simply to many negatives and the odds are stacked against investors. Funding issues ar making it hard for any small company to raise funds and investors are getting hammered as a result. Fair play 15p wasn't bad compared to many.
Posted at 12/7/2024 09:02 by timbo003
See below a few notes from Yesteday's AGM which I think covers the most important topics discussed, I might of missed out a few points, but to keep expeditious I have opted to post it as is.

Pharma Services

Research suggests that the average success rate of phase II (proof of Concept) clinical trials increases from about 28% to about 46% when a biomarker is involved with patient selection, so there is a lot of interest from Pharmas to use appropriate biomarkers when designing clinical studies.

Angle’s strategy is to have the pharma customer pay all development costs if they require a new biomarker assay based on Parsortix. Once developed the assay belongs to Angle and not the Pharma customer. The ideal strategy with a new partner is to go for depth, breadth and Halo (see below)

* Depth: once contracted to develop a parsortix assay, Angle look to employ the assay in all stages of clinical development, from Phase I to Phase IV.
* Breadth: seek opportunities to develop other Parsortix based assays for other drugs in the Pharma’s oncology portfolio.
* Halo: Leverage relationship with (named) Pharma customer to attract new Pharma customers.

Currently the emphasis is on protein assays, that is important and you can only do that with intact cells (biopsy or CTCs) – you cannot do this with conventional liquid biopsy (fragments of dead cells). However, protein assay is only the start, the really big opportunity will be when we get into molecular analysis, doing DNA and in particular RNA sequencing – you cannot do RNA analysis on ctDNA from liquid biopsies. Sequencing of cancer cells to look for mutations which have targeted therapy is a very big opportunity. There is a lot of Pharma investment going into that.


The current work focuses analysing CTCs in a small clinical trial using Eisai’s new HER2 ADC drug (£3K per blood sample analysed) , if successful this could lead to further Phase II and Phase III studies. Eisai have stated from the onset of the project that if the clinical program is successful they intend to licence and market the product with a companion diagnostic (i.e. parsortix based HER2 analysis on CTCs). This could ultimately lead to recurring revenues of between £20m and £100m/year to Angle.

Astra Zeneca

Two projects with AZ

* Parsortix based DDR (DNA Damage Response) assay.

DDR inhibitors are a new class of oncology drugs being investigated by numerous Pharmas including AZ

* Parsortix based Androgen Receptor assay

Discussions with AZ had been taking place over a number of years, contract agreed in broad terms, at the last minute AZ threw a curved ball and requested that the contract was arranged through, conducted extensive due diligence on Angle on behalf of AZ, however when it came to finalising the contract the terms and conditions were unacceptable to Angle, these stated that AZ would own the assay, this was unacceptable and Angle refused to sign, went back to AZ and came back with a new contract where Angle would own the assay with AZ bearing all costs for the development. have many large Pharma clients (see, and now Angle is on their books as an approved supplier which bodes well for the future.

In addition to Eisai and AZ there are ongoing contracts/collaborations with biotech customers: Artois, Cresendo, Immatics and Jubilant

Angle are also currently in discussions with 11 pharma / biotech customers (6 of them are house hold names) and hope to add one or possibly two of these to the list of customers this year, the plan is to get about 20 such customers signed up.

Recent Placing and open offer:

The fund raising environment at the time when fund raising discussions were taking place were fairly grim and share prices in the sector depressed. Many OEIC funds have been forced to make redemptions depressing share prices of their underlying investments and the amount of available funds available for OEICs to invest. For this round some institutional investors who would normally have participated in the funding roadshow didn’t want to cross the wall to be taken inside. Yet despite this situation the placing was oversubscribed whilst offering a relatively small discount.

Many existing holders participated in the funding round (the placing or open offer), 35% (approx.) of the funds were raised from US investors. The Angle BOD were pleased with the (small) discount achieved with the placing, but disappointed at the market’s reaction to the announcement with the share price trading below the placing price which meant a low uptake with the open offer.

One shareholder made the point that if Angle had made it clear in the RNS announcements (and the open offer document) that the placing was oversubscribed, it would probably have resulted in a better market reaction and a greater demand in the open offer (Good point I thought), Ian said they had never commented on this in previous announcements (but they don’t normally have open offers to accompany placings do they?). A couple of shareholders stated that they ducked the open offer as they didn’t want to pay 15p when they could buy in the market at 14p or thereabouts. I offered the suggestion of including a few out of the money warrants with the new shares, but Andrew said they had wanted to to keep the fund raise as Vanilla as possible.


There was a question on CellKeep. Andrew managed to produce one from his brief case which he showed us. It sounds like there has been potential interest in commercialisation, although it might require modifications for other applications (such as for CF) where the volume of fluid may be greater or smaller than the volume used for Parsortix samples (0.2ml) and I got the impression that this was not a top priority

Product Business

Selling Parsortix, consumables and (Portrait) assays to Hospitals and Universities remains a very important part of the overall commercial strategy as it provides additional incentive for pharma to adopt a companion diagnostic approach for their new drug developments, having an assay method close to hand at the hospital/near the patients makes going down the companion diagnostic route a more obvious choice for Pharma partners.
Posted at 27/6/2024 14:08 by ohwhatfun
If AGL had bitten the bullet, last fund raise, securing the amount they needed, then it would all be very exciting, new investors would be buying gambling on good fortune ahead.

Sadly they didn’t, and hence they have created a potential opening for the money market to kick them in the teeth, short term.

That said even with a revenue missed raise for £8-£10m at 8p it still balances out at 11-12p average for the whole raise.

But for a break even plan on a monthly basis end of 2025, considerably more than the typical cash burn rate will be needed, which means a higher fund raise amount.

Not that new investors will be moaning too much at £2m a month revenue or more in 18 months.

It stills sounds like a tall order at 10 times the last 6 months rate.
Posted at 21/6/2024 09:04 by miavoce
Not a disaster at all bones. If the £2m mattered to the company they would have raised the placing to £10m. The OO was tacked onto the fundraise as a sop to existing investors to give the opportunity to buy at the same price as the placing, but as it happened existing investors could get a better price in the market. It would have been nice to get the full £2m but it really wasn't important IMO (and on the plus side the failure to raise £2m limits the dilution).

With regard to the £6m forecast, I agree that this looks challenging given the H1 revenue. However the fact that the directors have expressed confidence that they will meet the £6m forecast indicates to me that they know something big is coming down the line. We shall see.
Posted at 18/6/2024 13:39 by yasx

I think you need to realise the information you are setting out is misleading, deliberately or otherwise. In any event, your musings have nil impact on the shares.

Just to clarify, it is not a case of they are struggling to get a raise 'away'. In fact, the Co. could quite easily have raised a further 2 million from investors at 15p had it elected to do so. The Co. indicated its intention to raise around £8.5M at 15p,by way of a placing and a direct subscription of shares. This was undertaken by a bookbuilding process and within 24 hours the Co. had managed to raise not 8.5M but just shy of £8.8M. In other words, more than they had indicated.

What the Co. also did was to ensure disenchanted shareholders get an opportunity to participate on similar terms, although this was heavily restricted (1 for 19 held). In other words, they were not keen to allow retail investors too much but did not wish to leave them out completely. As it happens, retail has got an even better opportunity to pick these up around 14p and so will likely not take up the offer.

None of that is significant - Angle have already raised 8.8M, and if they raise just around a million less than what they potentially could have had all shareholders taken up the offer, then it is hardly a game changer. If the shares were to rise over the next few days, then retail holders still have the opportunity to take up the offer. But, it is not a major issue if they don't and the Co has already raised 88pc of the maximum it intended to.

You can happily have mine at 25p - I will remind you when it gets there.
Posted at 10/6/2024 09:59 by ohwhatfun

No not distressed and clear £8m is not enough.

To go for the usual £20m would have involved cutthroat distressed levels.

Challenging re the forecast is tame word, it is highly unlikely due to the nature of how long deals take.

£900k from 3 so only another 15 or so to come in quick time if they are on that level. Even with deals, as in the recent deals, not all the revenue falls into this year.

So logically by the times interims arrive, likely last working day of Sept, they will either need it all booked or declare the miss.

As it stands, lost business and up 5 times what they did in H1 needed, then it’s not looking good is it.

Then the begging bowl comes out at levels they avoided this time around

It’s a gamble, with poor looking odds.

£20m now, even £15m would have created new investors and confidence.

Clearly holders, some who have posted, also are wary and concerned about next 6 months due to the limited cash.

Punters are now gambling on news events to head off a slump in the share price

I hope deals do land, I don’t want private investors losing money on false looking promises.
Posted at 05/5/2024 10:52 by davidosh
For the whole of this long weekend any investor buying a ticket for the *Mello2024* event will be given the bonus of being able to bring a friend or family member completely free of charge. Worth getting a friend to join with you and halving the cost maybe...

Will end at market open on Tuesday as it is a bank holiday weekend so plenty of time to connect

Mello2024 investor conference takes place on the 22nd and 23rd May Do come and join us....another six companies added to the list today and another six to be announced on Monday.

We want to keep this important face to face engagement with companies going and it has been tough since Covid as many directors just want to do webinars as their only token offering to investors. If you want to ask private questions or check out body language it is impossible on webinars and investors need to network with each other too.

Please support us and encourage companies/ management teams you are in contact with to come along to Mello2024 in Chiswick on 22nd or 23rd May

Mello2024 – Mello Events

If you have never been to one of our two day conferences before then clearly you are missing a great opportunity to engage with management teams and also network with hundreds of likeminded investors so we are offering virgin tickets at just £30 for either of the days so that you can see what it is all about.....a big discount from £99.00 and if you do not agree having spent the day with us I will give you an annual pass to our virtual shows on top. I just want investors engaging with all these quality smaller companies. This offer is only if you have never attended before so please be fair to all those who pay much more.... Simply enter the code NEW2MELLO24 BUY NOW:
Posted at 10/1/2024 23:26 by 5oletrader
(Addition to my last post)• Institutional Investors often have SPECIFIC PREFERENCEs that they would like to convey to the COMPANIES in their portfolio. Investors have various mechanisms for INFLUENCING COMPANIES.-• Global Frontier Investments LLC - Holds AGL & Accenture (ACN). ACN works closely with ROCHE. Remember the word - INFLUENCE.-I note this guy Maxim Lewinz is employed by ACN - involved in their Life Science Strategy. He published a piece on 8th JAN24 titled:• WILL 2024 BE A LEAP YEAR FOR LIQUID BIOPSY?-"LIQUID BIOPSY going MAINSTREAM may have several IMPLICATIONS that BIOPHARMA companies are already STARTING to PREPARE for." This includes:• To Consider PARTNERING with select LIQUID BIOPSY COMPANIES to build competitive advantage, e.g., in developing targeted oncology products.-FUNDs from FINANCIAL INVESTORs are pouring into companies like Guardant Health, Natera and ILLUMINA, reflecting a BULLISH SENTIMENT around the LIQUID BIOPSY MARKET. This is fueled by several factors:• Increasing SUPPORT from REGULATORS, most importantly demonstrated by FDA's 2022 guidance document "Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development"• INCREASING number of oncology TRIALS using LIQUID BIOPSY• Upcoming LAUNCH of multiple KEY PRODUCTs-Article here: the interest of IMPARTIALITY and opportunities for you to DYOR (for rebuttals and investigation) into the Liquid Biopsy space - here are some companies for you:• PERSONALIS• QIAGEN• MYRIAD GENETICS• EXACT SCIENCES• NEOGENOMICS• NATERA• GUARANT• ILLUMINA the Bears and Negative Nancy - I like to present 'evidence' for those with Inquisitive Minds. I'm open to reading your counter arguments - just present evidence? I digress.-In closing - Today's RNS shows the increased holding from an Institutional Investor. We should be responding with a one word question - WHY?-ATB
Posted at 26/11/2023 17:51 by 5oletrader
One for the diary? Plugging AGL to US investors.I note this coming week on Thursday 30th Nov at 17:00GMT - AGL will be presenting at the Small Cap Growth Virtual Investor Conference. is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Your Recent History

Delayed Upgrade Clock